Recipharm in discussions with Alcon regarding long-term manufacturing agreement

Recipharm is currently in discussions with Alcon and has reached agreement in principle to enter into a long-term manufacturing agreement for a range of ophthalmology products. As part of this arrangement, Recipharm will also acquire Alcon’s manufacturing facility located in Kaysersberg, France.  The 260 people currently employed at the Kaysersberg site would transfer and continue to be offered employment by Recipharm following the date of the sale. Further details will be made available following the end of consultation with the Works Council of Alcon and finalisation of the negotiations.

For more information please visit www.recipharm.com or contact:
Björn Westberg, CFO, bjorn.westberg@recipharm.com, +46 8 602 46 20
Mark Quick, EVP Corporate Development, mark.quick@recipharm.com, +44 1 925714263

This information is published in accordance with the Swedish Securities Market Act, the Swedish Financial Instruments Trading Act and/or the regulations of NASDAQ Stockholm. This information was submitted for publication on 7 September 2015, at 08:30 am CET.

About Recipharm
Recipharm is a leading CDMO (Contract Development and Manufacturing Organisation) in the pharmaceutical industry employing some 2,200 employees.  Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material including API and pharmaceutical product development. Recipharm manufactures more than 400 different products to customers ranging from Big Pharma to smaller research- and development companies. Recipharm’s turnover is approximately SEK 3.3 billion and the Company operates development and manufacturing facilities in Sweden, France, the UK, Germany, Spain, Italy and Portugal and is headquartered in Jordbro, Sweden. The Recipharm B-share (RECI B) is listed on NASDAQ Stockholm.

For more information on Recipharm and our services, please visit www.recipharm.com      

Recipharm AB (publ)
Corporate identity number 556498-8425
Address Lagervägen 7, SE-136 50 Jordbro, Sweden, Telephone 46 8 602 52 00, Fax 46 8 81 87 03

www.recipharm.com

About Us

About RecipharmRecipharm is a leading CDMO (Contract Development and Manufacturing Organisation) in the pharmaceutical industry employing some 6,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, and pharmaceutical product development. Recipharm manufactures several hundred different products to customers ranging from Big Pharma to smaller research- and development companies. Recipharm’s turnover is approximately SEK 6.4 billion and the company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm. For more information on Recipharm and our services, please visit www.recipharm.com

Subscribe

Documents & Links